TY  - JOUR
AU  - Young, Jim
AU  - Weis, Nina
AU  - Hofer, Harald
AU  - Irving, William
AU  - Weiland, Ola
AU  - Giostra, Emiliano
AU  - Pascasio, Juan Manuel
AU  - Castells, Lluis
AU  - Prieto, Martin
AU  - Postema, Roelien
AU  - Lefevre, Cinira
AU  - Evans, David
AU  - Bucher, Heiner C
AU  - Calleja, Jose Luis
PY  - 2017
DO  - 10.1186/s12879-016-2106-x
UR  - http://hdl.handle.net/10668/10747
T2  - BMC infectious diseases
AB  - There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than...
LA  - en
KW  - Daclatasvir
KW  - Direct-acting antivirals
KW  - Effectiveness
KW  - Hepatitis C
KW  - Sofosbuvir
KW  - Antiviral Agents
KW  - Bayes Theorem
KW  - Carbamates
KW  - Cohort Studies
KW  - Drug Therapy, Combination
KW  - Europe
KW  - Female
KW  - Hepatitis C, Chronic
KW  - Humans
KW  - Imidazoles
KW  - Liver Cirrhosis
KW  - Liver Transplantation
KW  - Male
KW  - Middle Aged
KW  - Pyrrolidines
KW  - Retrospective Studies
KW  - Ribavirin
KW  - Sofosbuvir
KW  - Treatment Outcome
KW  - Valine
TI  - The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
TY  - research article
VL  - 17
ER  -